Dr. Schenkein joined Agios in August 2009 as the Chief Executive Officer and a member of our board of directors and has been a hematologist and medical oncologist for more than 20 years. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the Senior Vice President, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio.
While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the Senior Vice President of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and Non-Hodgkin's lymphoma. He currently serves on the board of directors of Foundation Medicine, Inc., bluebird bio, Inc., and Denali Therapeutics Inc.
Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.
What is David P. Schenkein's net worth?
The estimated net worth of David P. Schenkein is at least $1.96 million as of April 3rd, 2023. Dr. Schenkein owns 117,879 shares of Denali Therapeutics stock worth more than $1,957,970 as of May 1st. This net worth approximation does not reflect any other assets that Dr. Schenkein may own. Learn More about David P. Schenkein's net worth.
How do I contact David P. Schenkein?
Has David P. Schenkein been buying or selling shares of Denali Therapeutics?
David P. Schenkein has not been actively trading shares of Denali Therapeutics during the past quarter. Most recently, David P. Schenkein sold 25,000 shares of the business's stock in a transaction on Monday, December 21st. The shares were sold at an average price of $90.06, for a transaction totalling $2,251,500.00. Learn More on David P. Schenkein's trading history.
Who are Denali Therapeutics' active insiders?
Are insiders buying or selling shares of Denali Therapeutics?
In the last twelve months, insiders at the sold shares 31 times. They sold a total of 210,517 shares worth more than $4,491,915.99. The most recent insider tranaction occured on April, 15th when Director Vicki L Sato sold 1,666 shares worth more than $30,471.14. Insiders at Denali Therapeutics own 7.9% of the company.
Learn More about insider trades at Denali Therapeutics. Information on this page was last updated on 4/15/2024.
